NRIX Nurix Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1549595 · Fiscal year ends 11/30
Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY738.8%
TTM net income YoY220.5%
TTM EPS YoY181.8%
Revenue 3-yr CAGR117.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin41.3%
Net margin42.0%
FCF margin52.7%
EBITDA margin42.5%
Returns
ROE44.0%
ROA34.3%
ROIC (approx.)84.5%
Asset turnover0.82x
Leverage & solvency
Liabilities / assets19.0%
Debt / equity0.00x
Current ratio8.44x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-11-30 | FY20242024-11-30 | FY20232023-11-30 | FY20222022-11-30 | FY20212021-11-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M |
| R&D expense | $316.90M | $221.63M | $189.15M | $184.50M | $116.43M |
| SG&A expense | $52.74M | $45.94M | $42.90M | $38.00M | $31.20M |
| Operating income | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M |
| Pretax income | -$263.70M | -$193.30M | -$143.95M | -$180.36M | -$117.06M |
| Income tax | $760,000 | $270,000 | $0 | $0 | $131,000 |
| Net income | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M |
| EBITDA | -$276.93M | -$203.71M | -$147.53M | -$178.52M | -$115.10M |
| EPS (basic) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 |
| EPS (diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 |
| Dividends declared per share | 0.00 | 0.00 | — | — | — |
| Weighted avg. shares (diluted) | 86.67M | 67.12M | 54.34M | 48.61M | 42.90M |
| Balance sheet | |||||
| Cash & equivalents | $246.96M | $110.90M | $54.63M | $64.47M | $80.51M |
| Short-term investments | — | — | — | $244.67M | $215.21M |
| Receivables | $0 | $0 | — | $0 | $6.00M |
| Current assets | $606.82M | $619.39M | $295.50M | $318.45M | $311.12M |
| PP&E, net | $22.49M | $17.76M | $16.81M | $17.16M | $11.34M |
| Total assets | $688.13M | $669.34M | $355.60M | $416.76M | $476.77M |
| Current liabilities | $86.47M | $95.85M | $86.96M | $70.66M | $66.26M |
| Total liabilities | $149.39M | $142.35M | $155.10M | $113.06M | $134.47M |
| Shareholders' equity | $538.75M | $526.99M | $200.49M | $303.70M | $342.30M |
| Shares outstanding | 101.81M | 75.87M | 48.72M | 47.17M | 44.66M |
| Cash flow statement | |||||
| Operating cash flow | -$249.47M | -$172.58M | -$81.36M | -$159.81M | -$84.36M |
| Capital expenditure | $14.00M | $9.27M | $8.40M | $12.24M | $5.66M |
| Free cash flow | -$263.47M | -$181.86M | -$89.77M | -$172.05M | -$90.03M |
| Investing cash flow | $147.85M | -$257.71M | $68.30M | $27.20M | -$108.25M |
| Financing cash flow | $238.64M | $485.67M | $3.22M | $117.19M | $153.88M |
| Depreciation & amortization | $8.74M | $9.32M | $7.53M | $5.35M | $2.79M |
| Stock-based compensation | $37.97M | $33.93M | $33.67M | $28.13M | $15.80M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.